Skip to main content

NTRA

Stock
Health Care
Diagnostics & Research

Performance overview

NTRA Price
Price Chart

Forward-looking statistics

Beta
1.19
Risk
46.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees3K
Market cap$13.7B

Fundamentals

Enterprise value$22.3B
Revenue$1.8B
Revenue per employee—
Profit margin-10.36%
Debt to equity15.78

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.47
Dividend per share—
Revenue per share$14.28
Avg trading volume (30 day)$210M
Avg trading volume (10 day)$228M
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+3.8
Liquidity+0.6
Inflation+1.1
Commodities-0.0
Interest Rates-3.2

Valuation

Dividend yield0.00%
PEG Ratio-133.69
Price to sales12.06
P/E Ratio-133.69
Enterprise Value to Revenue12.16
Price to book17.74

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.

Zacks Investment Research (May 8, 2025)
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making large, measured bets. His latest large wager has paid off.

Benzinga (December 20, 2024)
Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD

The Cigna Group reported a $739 million third quarter profit despite a $1 billion loss on its investment in clinic operator VillageMD.

Forbes (October 31, 2024)
The Committee's Comeback Kids: Trade Desk, Sweetgreen, Natera, Samsara, PayPal and Leidos

The Investment Committee discuss their comeback stocks following the August 5th lows.

CNBC Television (August 29, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free